GLP-1/GIP receptor (dual)

Assets acting on this target.

Class
Dual GLP-1/GIP receptor agonist

The GLP-1 and GIP receptors are class B G-protein-coupled receptors expressed on pancreatic beta cells, in the central nervous system, and in peripheral tissues including adipose tissue. Both are activated physiologically by incretin hormones released from the gut after eating, and both potentiate insulin secretion in a glucose-dependent manner, meaning insulin release is amplified only when blood glucose is elevated, which limits the risk of dangerously low blood sugar. GLP-1 receptor activation additionally suppresses glucagon secretion, slows gastric emptying, and promotes satiety signals in the brain, contributing to reduced food intake. GIP receptor activation contributes to lipid handling in fat tissue and may add metabolic benefits distinct from those of GLP-1 alone. A dual agonist engages both receptors simultaneously, aiming to combine the glucose-lowering and appetite-suppressing effects of GLP-1 signaling with the additional metabolic contributions of GIP signaling, with the goal of achieving greater improvements in blood sugar control and body weight than agonism at either receptor alone. This mechanism is broadly relevant to type 2 diabetes, where glycemic control is the primary aim, and to obesity, where appetite and energy balance are the therapeutic targets.

By indication

Related mechanisms

GLP-1/GIP receptor (dual) drugs compared

13 drugs, stage by indication
13 drugs acting on GLP-1/GIP receptor (dual): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Tirzepatide (Mounjaro)MounjaroEli Lilly, Tanabe Pharma CorporationpeptideApprovedApproved in Atherosclerotic Cardiovascular Disease; Approved in Type 2 Diabetes
Tirzepatide (Zepbound)ZepboundEli LillypeptideApprovedApproved in Obesity; Phase 3 in Crohn's Disease; Phase 3 in Psoriasis; Phase 3 in Psoriatic Arthritis
BGM0504BrightGene Bio-Medical Technology, China Resources Sanjiu Medical & PharmaceuticalpeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
BrenipatideEli LillypeptidePhase 3Phase 3 in Alcohol Use Disorder; Phase 3 in Major Depressive Disorder; Phase 2 in Asthma; Phase 2 in Bipolar Disorder; Phase 2 in Chronic Obstructive Pulmonary Disease; Phase 2 in Opioid Use Disorder; Phase 2 in Schizophrenia; Phase 1 in Obesity
enicepatideChugai Pharma, RochepeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
HDM1005Hangzhou Zhongmei Huadong PharmaceuticalpeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
olatorepatideHansoh Pharmaceutical Group, Regeneron PharmaceuticalspeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes; Phase 2 in Hidradenitis Suppurativa
RAY1225Guangdong Raynovent Biotech, Qilu PharmaceuticalpeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
ribupatideJiangsu Hengrui Pharmaceuticals, Kailera TherapeuticspeptidePhase 3Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 3 in Obesity; Phase 3 in Type 2 Diabetes; Phase 2 in Heart Failure
VK2735Viking TherapeuticspeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
NNC0519-0130Novo NordiskpeptidePhase 2Phase 2 in Chronic Kidney Disease; Phase 2 in Obesity; Phase 2 in Type 2 Diabetes
THDBH120Tonghua Dongbao PharmaceuticalpeptidePhase 2Phase 2 in Obesity
KP405Kariya PharmaceuticalspeptidePhase 1Phase 1 in Parkinson's Disease

← all mechanisms